Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer

BACKGROUND: Concurrent chemoradiotherapy (CCRT) followed by durvalumab is the standard of care for unresectable locally-advanced non-small cell carcinoma (LA-NSCLC). However, a major concern about administration of durvalumab after CCRT is whether the incidence of symptomatic radiation pneumonitis (...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayahara, Hiroshi, Uehara, Kazuyuki, Harada, Aya, Kitatani, Keiji, Yabuuchi, Tomonori, Miyazaki, Shuichirou, Ishihara, Takeaki, Kawaguchi, Hiroki, Kubota, Hikaru, Okada, Hideaki, Ninomaru, Taira, Shindo, Chihiro, Hata, Akito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760798/
https://www.ncbi.nlm.nih.gov/pubmed/35033139
http://dx.doi.org/10.1186/s13014-021-01979-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760798/
https://www.ncbi.nlm.nih.gov/pubmed/35033139
http://dx.doi.org/10.1186/s13014-021-01979-z

Ejemplares similares